InfraReDx Inc. is on a roll this fall. The Burlington, Mass.-based medical device maker won 510(k) clearance from the Food & Drug Administration in early September for its LipiScan IVUS coronary imaging system and pulled in $21 million in an equity offering a month later, which it plans to use to fund the U.S. rollout of the device.
The LipiScan IVUS uses both so-called “near-infrared” spectroscopy and intravascular ultrasound technology to give cardiologists a grayscale IVUS image of a coronary artery, along with a map of lipid core coronary plaques within a blood vessel.